Literature DB >> 18182645

Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age.

Scott Perry1, Philip Holt, Michael Benatar.   

Abstract

Newer antiepileptic drugs are reported to have better side-effect profiles than traditional antiepileptics, although the evidence to this effect and their efficacy is limited. We compare the efficacy and tolerability of levetiracetam and carbamazepine monotherapy in children with partial epilepsy < or = 16 years of age. We identified 86 patients (66 levetiracetam, 20 carbamazepine) treated with initial monotherapy for partial epilepsy and followed for > or = 6 months. Efficacy was based on the number of patients achieving seizure freedom of > or = 6 months. Tolerability was based on parent-and patient-reported side effects. Forty-eight (73%) subjects on levetiracetam and 13 (65%) subjects on carbamazepine achieved 6 months of seizure freedom. A total of 70% of patients on carbamazepine and 45% of those on levetiracetam had at least 1 adverse event while on monotherapy (P = .07). Levetiracetam and carbamazepine monotherapy demonstrate similar efficacy for treatment of partial epilepsy and are well tolerated in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18182645     DOI: 10.1177/0883073807309784

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

Review 1.  Levetiracetam in childhood epilepsy.

Authors:  Alberto Verrotti; Ebe D'Adamo; Pasquale Parisi; Francesco Chiarelli; Paolo Curatolo
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

2.  Scalp recorded spike ripples predict seizure risk in childhood epilepsy better than spikes.

Authors:  Mark A Kramer; Lauren M Ostrowski; Daniel Y Song; Emily L Thorn; Sally M Stoyell; McKenna Parnes; Dhinakaran Chinappen; Grace Xiao; Uri T Eden; Kevin J Staley; Steven M Stufflebeam; Catherine J Chu
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

3.  A Comparative Study on the Efficacy of Levetiracetam and Carbamazepine in the Treatment of Rolandic Seizures in Children: An Open-Label Randomized Controlled Trial.

Authors:  Parisa Ahadi; Jafar Nasiri; Mohammad Reza Ghazavi; Toktam Mosavian; Vahid Mansouri
Journal:  J Res Pharm Pract       Date:  2020-06-26

Review 4.  Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review.

Authors:  Amerins Weijenberg; Oebele F Brouwer; Petra M C Callenbach
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

5.  Beta oscillations in the sensorimotor cortex correlate with disease and remission in benign epilepsy with centrotemporal spikes.

Authors:  Dan Y Song; Sally M Stoyell; Erin E Ross; Lauren M Ostrowski; Emily L Thorn; Steven M Stufflebeam; Amy K Morgan; Britt C Emerton; Mark A Kramer; Catherine J Chu
Journal:  Brain Behav       Date:  2019-02-20       Impact factor: 2.708

6.  Levetiracetam (levebel) Versus Carbamazepine Monotherapy for Focal Epilepsy in Children: A randomized clinical trial.

Authors:  Javad Akhondian; Farah Ashrafzadeh; Hossein Eslamiyeh
Journal:  Iran J Child Neurol       Date:  2020

7.  Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age.

Authors:  Justine Cormier; Catherine J Chu
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-21       Impact factor: 2.570

8.  Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures.

Authors:  Swaroop Hassan Suresh; Ananya Chakraborty; Akash Virupakshaiah; Nithin Kumar
Journal:  Epilepsy Res Treat       Date:  2015-12-20

9.  Timing matters: Impact of anticonvulsant drug treatment and spikes on seizure risk in benign epilepsy with centrotemporal spikes.

Authors:  Wenting Xie; Erin E Ross; Mark A Kramer; Uri T Eden; Catherine J Chu
Journal:  Epilepsia Open       Date:  2018-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.